middle.news
Chimeric Therapeutics Unveils Promising AML Trial Results with CORE-NK Therapy
9:51am on Thursday 2nd of October, 2025 AEST
•
Healthcare
Read Story
Chimeric Therapeutics Unveils Promising AML Trial Results with CORE-NK Therapy
9:51am on Thursday 2nd of October, 2025 AEST
Key Points
57% clinical response rate in high-risk frontline AML patients
Two new complete responses added to previous trial results
No dose-limiting toxicities or severe immune-related side effects observed
CORE-NK cells persisted in patients’ blood beyond two weeks
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
CHM
OPEN ARTICLE